Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Gerald M. Walsh"'
Autor:
Brian A. Van Tine, Mark Agulnik, Richard D. Olson, Gerald M. Walsh, Arthur Klausner, Nicole E. Frank, Todd T. Talley, Mohammed M. Milhem
Publikováno v:
Cancer Medicine, Vol 8, Iss 6, Pp 2994-3003 (2019)
Abstract Background 13‐Deoxy, 5‐iminodoxorubicin (GPX‐150) is a doxorubicin (DOX) analog synthesized to reduce the formation of reactive oxygen species and the cardiotoxic metabolite, doxorubiciniol, the two pathways that are linked to the irre
Externí odkaz:
https://doaj.org/article/6736cc86265f4013b5503c366edeaf37
Autor:
Raymond J. Hohl, Sarah A. Holstein, Richard D. Olson, James Bigelow, Gerald M. Walsh, Robert E. Vestal
Publikováno v:
Investigational New Drugs. 33:594-602
Purpose 5-imino-13-deoxydoxorubicin (DIDOX; GPX-150) is a doxorubicin analog modified in two locations to prevent formation of cardiotoxic metabolites and reactive oxygen species. Preclinical studies have demonstrated anti-cancer activity without car
Publikováno v:
Investigational new drugs. 34(6)
Purpose A novel doxorubicin (DOX) analog, 13-deoxy, 5-iminodoxorubicin (DIDOX), was synthesized to prevent quinone redox cycling and alcohol metabolite formation, two prevailing hypotheses of anthracycline cardiotoxicity. The chronic cardiotoxicity o
Publikováno v:
International Immunopharmacology. 7:734-743
We report that the novel anthracycline analog, 13-deoxy, 5-iminodoxorubicin (DIDOX), represents a potentially new class of immunosuppressive agents. DIDOX has been structurally modified from the parent compound, doxorubicin, to remove the carbonyl gr
Autor:
Brian A. Van Tine, Arthur Klausner, Gerald M. Walsh, Mohammed M. Milhem, Richard D. Olson, Mark Agulnik
Publikováno v:
Journal of Clinical Oncology. 34:11019-11019
11019Background: 5-imino-13-deoxydoxorubicin (GPX-150) is a doxorubicin (dox) analog that has been modified to retain the ability to inhibit topoisomerase 2a while simultaneously lacking the inhibi...
Autor:
Yang Po-Chang, Tugrul T. Kararli, Maribeth Babler, Gerald M. Walsh, Steve Bittner, Bahram Farhadieh
Publikováno v:
International Journal of Pharmaceutics. 102:177-184
The absolute bioavailabilities of three renin inhibitor compounds, one uncharged (compound I) and two positively charged (compounds II and III), were found to be comparable (1—3%). To determine the role of intestinal transport and first pass liver
Autor:
Shanta Bantia, Heather S. Turner, Karen O. Allen, John A. Montgomery, Daunte L. Barlow, Gerald M. Walsh, Albert F. LoBuglio, Robert M. Conry
Publikováno v:
Immunopharmacology. 40(1)
The antiproliferative effect of BCX-34 was tested in normal human peripheral blood mononuclear cells (PBMCs) induced to proliferate with OKT3, tetanus toxoid, the mixed lymphocyte reaction, or IL-2. In the case of OKT3, tetanus toxoid, or the MLR the
Autor:
Y. Sudhakar Babu, Shanta Bantia, Gillian M. Air, Sandya L Ananth, Gerald M. Walsh, Anita A. Ghate
Publikováno v:
Antimicrobial agents and chemotherapy. 42(4)
Influenza neuraminidase (NA) plays an important role in viral replication, and characterization of viruses resistant to NA inhibitors will help elucidate the role of active-site residues. This information will assist in designing better inhibitors ta
Publikováno v:
Journal of chromatography. B, Biomedical sciences and applications. 690(1-2)
9-(3-Pyridylmethyl)-9-deazaguanine (BCX-34), a new purine nucleoside phosphorylase inhibitor, has selective immunosuppressive activity with potential therapeutic value in T-cell-mediated diseases. We now report a sensitive, specific and reproducible